NASDAQ:INM
InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc. reported net income of −$12.6M in fiscal 2026. The diluted share count rose 326.6%.Summary generated from InMed Pharmaceuticals Inc.'s SEC filings. Latest annual report filed Sep 9, 2026.
Key statistics
Fiscal 2026 from SEC filings. MethodologyRevenue (FY26)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−173.1%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+326.6%
Financials
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | 1 | 4 | 5 | 5 | n/a |
| Operating income | −19 | −8 | n/a | n/a | n/a |
| Net income | −19 | −8 | −8 | −8 | −13 |
| Free cash flow | −16 | −7 | −7 | n/a | n/a |
Recent filings
- 4Insider transaction report
Oct 8, 2026 - 4Insider transaction report
Oct 5, 2026 - 8-KNotice of delisting or listing-rule failure
Sep 18, 2026 - 10-KAnnual report for the fiscal year ended Jun 30, 2026
Sep 9, 2026 - 8-KRegulation FD disclosure
Jul 22, 2026 - 8-KEntry into a material agreement
Jul 10, 2026 - 8-KOther events
Jun 10, 2026 - 8-KEntry into a material agreement
May 19, 2026